Preclinical data in BRAF-mutated cells showed that therapy targeting the MAPK pathway may induce immunological changes (increased CD4+ and CD8+ lymphocyte infiltrate, reduced release of immunosuppressive cytokines, and upregulated expression of the major histocompatibility complex I [149,150]), promoting a more favorable tumor microenvironment that may boost the tumor responses driven by ICIs. The gene discussed is BRAF; the disease is neoplasm.